NCL  
Nanotechnology Characterization Laboratory Skip Navigation
 

Assay Cascade Protocols
Frederick National Lab
Nanotechnology Characterization Laboratory

Physicochemical Characterization Method ID
 

Size, Size Distribution

 
    Measuring the Size of Nanoparticles in Aqueous Media Using Batch-Mode DLS
Old Television Clip Art See the DLS Video Protocol demonstration
NIST-NCL PCC-1
    Size Measurement of Nanoparticles Using Atomic Force Microscopy NIST-NCL PCC-6
    Measuring the Size of Nanoparticles Using Transmission Electron Microscopy NIST-NCL PCC-7
    Analysis of Gold Nanoparticles by Electrospray Differential Mobility Analysis NIST-NCL PCC-10
    Measuring the Size of Colloidal Gold Nanoparticles Using High-Resolution Scanning Electron Microscopy NIST-NCL PCC-15
  Topology
Molecular Weight
Aggregation
Purity
Chemical Composition
    Determination of Gold in Rat Tissue with Inductively Coupled Plasma-Mass Spectrometry NIST-NCL PCC-8
    Determination of Gold in Rat Blood with Inductively Coupled Plasma-Mass Spectrometry NIST-NCL PCC-9
    Method for Determination of the Mass Fraction of Particle-Bound Gold in Suspensions of Gold Nanoparticles NIST-NCL PCC-11
    Quantification of Free and Chelated Gadolinium Species in Nanoemulsion-Based Magnetic Resonance Imaging Contrast Agent Formulations using Hyphenated Chromatography Methods NIST-NCL PCC-14
  Surface Characteristics
Functionality
Zeta Potential
    Measuring Zeta Potential of Nanoparticles PCC-2
    Measuring the Electrolytic Conductivity of Nanoparticle Suspensions NIST-NCL PCC-12
    Measuring the pH of Nanoparticle Suspensions NIST-NCL PCC-13
  Stability
Solubility

 
In Vitro Characterization Method ID
  Sterility  
    Detection of Endotoxin Contamination  
      End Point Chromogenic LAL Assay STE-1.1
      Kinetic Turbidity LAL Assay STE-1.2
      Gel-Clot LAL Assay STE-1.3
    Detection of Microbial Contamination STE-2
    Detection of Mycoplasma Contamination STE-3
  Targeting  
    Cell Binding/Internalization  
  Drug Release  
    In Vitro Blood Partitioning Assay GTA-13
  In Vitro Immunology  
    Blood Contact Properties  
      Analysis of Hemolytic Properties of Nanoparticles ITA-1
      Analysis of Platelet Aggregation ITA-2
      Analysis of Nanoparticle Interaction with Plasma Proteins by 2D PAGE ITA-4
      Qualitative Analysis of Total Complement Activation by Western Blot ITA-5.1
      Quantitative Analysis of Complement Activation ITA-5.2
      Coagulation Assay ITA-12
    Cell-Based Assays  
      Mouse Granulocyte Macrophage Colony-Forming Unit Assay ITA-3
      Leukocyte Proliferation Assay ITA-6
      Macrophage/Neutrophil Function (4 categories):  
        Detection of Nitric Oxide Production by RAW 264.7 Macrophage Cell Line ITA-7
        Chemotaxis Assay ITA-8
        Phagocytosis Assay ITA-9
      Measurement of Nanoparticle Effects on Cytotoxic Activity of NK Cells by Label-Free RT-CES System ITA-11
      Analysis of Nanoparticle Effects on Maturation of Monocyte Derived Dendritic Cells In Vitro ITA-14
      In Vitro Induction of Leukocyte Procoagulant Activity by Nanoparticles ITA-17
  Toxicity  
    Oxidative Stress  
      Hep G2 Hepatocyte Glutathione Assay GTA-3
      Hep G2 Hepatocyte Lipid Peroxidation Assay GTA-4
      Hepatocyte Primary ROS Assay GTA-7
    Cytotoxicity (necrosis)  
      LLC-PK1 Kidney Cytotoxicity Assay (MTT and LDH Release) GTA-1
      Hep G2 Hepatocarcinoma Cytotoxicity Assay (MTT and LDH Release) GTA-2
    Cytotoxicity (apoptosis)  
      LLC-PK1 Kidney Apoptosis Assay (Caspase 3 Activation) GTA-5
      Hep G2 Hepatocarcinoma Apoptosis Assay (Caspase 3 Activation) GTA-6
      Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay (Caspase 3/7 Activation) GTA-14
    Autophagy  
      Autophagic Dysfunction Assay: Qualitative Analysis of MAP LC3I to LC3-II Conversion by Western Blot GTA-11
      Autophagic Dysfunction in LLC-PK1 Cells GTA-12
       

In Vivo Characterization

 
  Efficacy  
    Therapeutic  
    Imaging  
  Disposition study  
    Tissue Distribution  
    Clearance  
    Half-life  
    Systemic exposure (plasma AUC)  
  Single and Repeat-Dose Toxicity  
  Immunotoxicity  
     
     
 
  Questions?
For questions, comments, or to leave feedback regarding any of the NCL's Assay Cascade Protocols, please click here.
National Cancer InstituteDepartment of Health and Human ServicesNational Institutes of HealthFirstGov.govNCI - Alliance for Nanotechnology in Cancer
National Cancer Institute U.S. National Institutes of Health www.cancer.gov Nanotechnology Characterization Lab